| HOME >> BIOLOGY >> TECHNOLOGY |
KANSAS CITY, Kan., June 1 /PRNewswire/ -- Oncimmune LLC, maker of EarlyCDT-Lung™, a simple blood test that aids physicians in risk assessment and the early detection of lung cancer, today announced validation study results demonstrating the diagnostic and economic benefits of a standardized and reproducible autoantibody laboratory test (AABT) that may significantly improve the prognosis for lung cancer patients. Currently, lung cancer is responsible for more deaths than breast, prostate, colon, liver, kidney and melanoma cancers combined.(1)
Studies were completed with 573 patients known to have lung cancer who were matched against normal patients (no lung cancer) for the same age, sex and smoking history. The test, which is regulated under CLIA, has 40% sensitivity and 90% specificity. This means that the test detects 40% of lung cancers, including early stage disease (Stages I and II), and the overall accuracy of the test is greater than 88%. This performance compares favorably with other well known tests such as mammography in younger women or in the case of lung cancer, where EarlyCDT-Lung performance is at least twice as good as CT. Study findings suggest that the autoantibody test is not influenced by sex, ethnicity, geographic location of patients or the presence of benign autoimmune diseases. Previous studies have shown that autoantibodies can be detected up to five years before tumors can be seen in routine diagnostic imaging procedures such as CT.(2)
Oncimmune researchers also set forth the modeled cost-effectiveness of EarlyCDT-Lung as an aid to lung cancer diagnosis, with an estimated $6,000 potential cost savings for every QALY (quality-adjusted life year) saved. Study results are being introduced in multiple poster presentations Jun
'/>"/>SOURCE Oncimmune LLC
Copyright©2010 PR Newswire.
All rights reserved
Related biology technology :
1. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
2. Lilly Oncology to Unveil More Than 50 Studies at ASCO 2010
3. Encorium Group, Inc. Announces New Business Contract Wins of $6.8 Million, Including Two Pivotal Phase III Studies for a Major Asian Technology Company
4. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
5. Mettler Toledo and PDS Pathology Data Systems Integrate Powerful Solutions for Faster and More Accurate Preclinical Studies
6. Scientific breakthrough in genetic studies of animal domestication
7. Zenith Biotech Introducing Novel StemQ(R) Hepatic and Neural Models for Use in Drug Discovery, Metabolism and Toxicology Studies, at The 49th Annual Meeting and ToxExpo In Salt Lake City, Utah, March 7-11, 2010, Booth #136
8. GeoVax Labs, Inc. Reports Data on Prototype Adjuvant - Supplemented HIV Vaccine Tested in Preclinical Animal Studies
9. Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies
10. S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
11. Wyle Personnel Take Part in Important Studies Aboard the International Space Station
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |